3654 results for «382»
3654 results
Artificial intelligence and advanced imaging in coronary interventions
19 May 2026 – From EuroPCR 2026
This session explores the integration of artificial intelligence with advanced imaging modalities in coronary interventions. Topics include quantitative myocardial blood flow assessment via co-registered CCTA and angiography, AI-guided real-time procedural support, novel video frame interpolation techniques, high-risk plaque identification through AI-derived OCT stress mapping, and validation...
STEMI presenting with cardiogenic shock
19 May 2026 – From EuroPCR 2026
This session covers acute management of STEMI presenting with cardiogenic shock, illustrating advanced interventional strategies and support devices such as ECMO, IABP, and Impella. It reviews complex clinical scenarios including acute left main occlusion and multivessel disease, offering critical insights into emergent care and decision-making.
Stent failure evaluation with intracoronary imaging
19 May 2026 – From EuroPCR 2026
This session provides an in-depth evaluation of stent failure using intracoronary imaging modalities such as IVUS and OCT. It presents diverse cases illustrating late drug-eluting stent failure, in-stent restenosis, neoatherosclerosis, and complications following rotational atherectomy, underscoring imaging's role in diagnosis and guiding reintervention.
Leaflet modification techniques during TAVI
19 May 2026 – From EuroPCR 2026
This session explores leaflet modification techniques during TAVI, focusing on complex valve-in-valve procedures supported by artificial intelligence-powered planning and advanced imaging. Case discussions cover challenges such as low valve-to-coronary distances, bi-leaflet obstruction, and strategies to maintain coronary flow and hemodynamic stability.
Transcatheter mitral valve replacement - LIVE case
20 May 2026 – From EuroPCR 2026
A 65‑year‑old woman with obesity (BMI 38.7), prior cardiac surgery (CABG to OM and LAD in 2012), and chronic kidney disease presented with symptomatic severe mitral regurgitation (Carpentier type III: type IIIa due to calcification and type IIIb post‑MI) with moderately reduced LVEF (45%).
A transcatheter mitral...
Pulmonary valve: the next frontier in adult structural interventions
19 May 2026 – From EuroPCR 2026
This session highlights the evolving role of the pulmonary valve in adult structural interventions. It reviews complex transcatheter pulmonary valve replacement (TPVR) cases, strategies for managing challenging right ventricular outflow tract anatomies, and percutaneous solutions for pulmonary artery stenosis and related complications.
New techniques and tips in CTO PCI
19 May 2026 – From EuroPCR 2026
This session presents new techniques and practical tips in chronic total occlusion (CTO) percutaneous coronary intervention (PCI). It covers innovative approaches such as the side-flap technique, simplified antegrade strategies for calcified lesions, and retrograde CTO techniques, providing valuable insights into overcoming challenging occlusions.
New frontiers: TAVI for aortic regurgitation with conventional and dedicated devices
20 May 2026 – From EuroPCR 2026
This session explores new frontiers in transcatheter aortic valve implantation (TAVI) for treating pure aortic regurgitation. It addresses the challenges inherent to this indication, reviews treatment approaches using conventional balloon-expandable and self-expandable devices, and presents recent data along with dedicated TAVI devices designed specifically for aortic...
POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?
02 Sep 2024
Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials
14 Nov 2021
Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.
Author
ESC/EACTS Valvular Heart Disease Guidelines 2021: updates from the 2017 Guidelines
29 Aug 2021
There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...
Author
Evidence base: current data on TAVI durability and long-term outcomes
18 Jun 2026
This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.
Author
Author
Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)
30 Oct 2024
Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.
Author
